Full studies available on PubMed
Since June 2021, when Novo Nordisks first obesity drug gained regulatory approval, shares of WW International (WW.O) , formerly Weight Watchers, have collapsed about 70%, despite the company unveiling a plan to distribute weight-loss drugs
For those using GLP-1 medications for weight management, reduced efficacy may manifest as weight loss plateau or regain
Some drugs have been proposed to accelerate -cell loss (e.g., glibenclamide and glyburide) [23], while other drugs such as peroxisome proliferator-activated receptor-gamma (PPAR) agonists, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, glycogen synthase kinase 3 (GSK3) inhibitors, or G protein-coupled receptor 40 (GPR40) agonists have been suggested to protect -cell function [16]
This variation may indicate distinct roles of peptides in organisms